Impact Factor 4.137 | CiteScore 4.28
More on impact ›
This section aims to publish significant clinical and basic research findings on all aspects related to hematologic malignancies, including the areas of acute and chronic leukemias, lymphomas and Hodgkin’s disease, plasma cell disorders, and stem cell transplantation. Our ultimate goal is to accelerate the communication in the field and stimulate clinical applications of advances in molecular research.
Specifically, we welcome papers on the following topics:
While the Hematologic Malignancies section is primarily centered on human studies, in vitro and animal studies that are closely related to research on humans are also welcome.
Indexed in: PubMed, PubMed Central, Scopus, Google Scholar, DOAJ, CrossRef, Chemical Abstracts Service (CAS), Science Citation Index Expanded, CLOCKSS
PMCID: all published articles receive a PMCID
Hematologic Malignancies welcomes submissions of the following article types: Case Report, Clinical Trial, Correction, Editorial, Hypothesis and Theory, Methods, Mini Review, Opinion, Original Research, Perspective, Review, Specialty Grand Challenge, Systematic Review and Technology and Code.
All manuscripts must be submitted directly to the section Hematologic Malignancies, where they are peer-reviewed by the Associate and Review Editors of the specialty section.
Avenue du Tribunal Fédéral 34
CH – 1005 Lausanne
Tel +41(0)21 510 17 40
Fax +41 (0)21 510 17 01
For all queries regarding manuscripts in Review and potential conflicts of interest, please contact firstname.lastname@example.org
For queries regarding Research Topics, Editorial Board applications, and journal development, please contact email@example.com